Pharming gets US FDA Acceptance for Priority Review of its NDA for Leniolisib
Pharming Group N.V., announced that it has got acceptance from the US Food and Drug Administration (FDA) for priority review of Pharming’s New Drug Application (NDA) for leniolisib, an oral and selective phosphoinositide 3-kinase delta inhibitor. The inhibitor is used to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and […]
Continue Reading